ANP (Atrial Natriuretic Peptide)
Also known as: Atrial Natriuretic Factor, ANF, Carperitide, Atriopeptin
Overview
Atrial Natriuretic Peptide (ANP) is a 28-amino acid peptide hormone released from cardiac atria in response to increased atrial pressure and volume overload. As the first natriuretic peptide identified (1981 by de Bold et al.), ANP established the concept of the heart as an endocrine organ. Carperitide, the synthetic recombinant ANP, is approved and widely used in Japan for acute heart failure, where it has accumulated substantial clinical evidence. ANP also has roles in regulating lipolysis, reducing inflammation, and suppressing the renin-angiotensin-aldosterone system.
Mechanism of Action
ANP binds natriuretic peptide receptor A (NPR-A) on vascular endothelial and smooth muscle cells, renal tubules, and adrenal gland, generating cGMP via guanylyl cyclase activity. cGMP-PKG signaling produces vasodilation, inhibits aldosterone and renin release, increases renal sodium and water excretion (natriuresis), and reduces sympathetic nervous system tone. In adipocytes, ANP activates PKA/HSL-mediated lipolysis via NPR-A and also through cGMP cross-activation of PKA. ANP is cleared primarily by NPR-C (clearance receptor) and neprilysin enzymatic degradation.
Potential Benefits
- Acute cardiac preload/afterload reduction
- Natriuresis and diuresis in heart failure
- Suppression of aldosterone and renin release
- Anti-fibrotic and anti-hypertrophic cardiac effects
- Adipocyte lipolysis stimulation
- Established therapeutic in Japan (Carperitide)
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Beginner | Hospital use only |
| Intermediate | N/A |
| Advanced | N/A |
| Cycle Duration | Acute use: 1-3 days |
Carperitide (recombinant human ANP) approved in Japan for acute HF. Not FDA-approved.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Intravenous 100%
Hospital IV infusion only.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving ANP (Atrial Natriuretic Peptide):
Acute HF Management (Japan)
Japanese acute HF protocol.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Storage | Refrigerate 2-8°C. Use within 24 hours of reconstitution. |
|---|
Hospital preparation only.
Need exact syringe measurements?
Amino Acid Sequence
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr (cyclic via disulfide Cys7-Cys23)
Side Effects & Safety
- Hypotension (primary dose-limiting effect)
- Headache
- Compensatory renal effects with prolonged use
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~2-5 minutes |
|---|---|
| Storage | Refrigerate lyophilized product at 2-8°C. Protect from light. |
Synergistic Compounds
The following compounds have been studied alongside ANP (Atrial Natriuretic Peptide) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.